Otsuka (OTCMKTS:OTSKY) Upgraded at Zacks Research

Zacks Research upgraded shares of Otsuka (OTCMKTS:OTSKY) from a strong sell rating to a hold rating in a research report sent to investors on Tuesday morning,Zacks.com reports.

A number of other analysts also recently weighed in on the company. The Goldman Sachs Group downgraded Otsuka from a “strong-buy” rating to a “strong sell” rating in a report on Friday, February 27th. UBS Group raised Otsuka to a “hold” rating in a report on Tuesday, January 27th. Finally, Morgan Stanley raised Otsuka to an “overweight” rating in a research note on Friday, January 23rd. One analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold”.

Otsuka Trading Down 1.6%

Shares of OTCMKTS OTSKY opened at $35.80 on Tuesday. The firm has a 50 day moving average price of $32.87 and a two-hundred day moving average price of $29.69. The stock has a market cap of $38.46 billion and a P/E ratio of 15.57. Otsuka has a 52-week low of $21.64 and a 52-week high of $36.55. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.67 and a current ratio of 2.17.

About Otsuka

Otsuka Pharmaceutical Co, Ltd., trading in the U.S. under the ticker OTCMKTS:OTSKY, is a global healthcare company headquartered in Tokyo, Japan. The firm’s core activities span the development, manufacturing and marketing of prescription pharmaceuticals, consumer healthcare products and nutraceuticals. Otsuka focuses its research on areas such as neuroscience, cardiovascular and renal therapies, and oncology, aiming to bring innovative treatments to patients worldwide.

Founded in 1964 by Busaburo Otsuka as a subsidiary of the Otsuka Group, the company has grown into a diversified healthcare enterprise over more than five decades.